The major protein constituents of amyloid deposits in Alzheimer's disease (AD) are the 40-residue ␤-amyloid (A␤) 
Introduction
A lzheimer's disease (AD) is the major cause of adultonset dementia and is characterized by an abundance of intraneuronal neurofibrillary tangles and extracellular amyloid plaques (Iqbal et al 1999; Selkoe 2000) . The major component of the amyloid plaques is the ␤-amyloid (A␤), a normally secreted small peptide that exists in two predominant forms: 1) the 40-residue A␤(1-40) and 2) the 42-residue A␤(1-42) (Figure 1 ). The A␤(1-40) and A␤(1-42) peptides differ in the absence or presence of two extra C-terminal residues. Both peptides result from the processing of a larger amyloid precursor protein (APP) (Hardy 1997) (Figure 1 ). The amyloid deposits are characterized by distinct tinctorial properties and fibrils of 7-10 nm in diameter, in which the primary components are aggregated proteins with antiparallel cross-␤-pleated sheet structures (Malinchik et al 1998; Teplow 1998) .
The biological functions of both the APP and the A␤ are currently unknown, although they are believed to play roles in neuronal homeostasis, cell adhesion, G protein coupling, and/or oxidative stress. Numerous genetic and cell viability studies support a key role for the A␤ peptide in AD neurodegeneration. The A␤ peptide becomes neurotoxic to cortical cell cultures when aggregated as amyloidlike ␤-sheet structures (Geula et al 1998; Iversen et al 1995; Pike et al 1995; Simmons et al 1994) . Biochemical studies also suggest that the longer, 42-residue A␤(1-42) is more pathogenic than the shorter 40-residue A␤(1-40) (Younkin 1995) , due to its greater in vitro tendency to aggregate and precipitate as amyloid (Barrow and Zagorski 1991) . Recent studies demonstrated that the A␤(1-42) is significantly elevated in cerebrospinal fluid of AD patients (Andreasen et al 1999; Jensen et al 1999; Kuo et al 1999; Wang et al 1999) .
On the basis of extensive biophysical measurements, in solution the A␤ peptide can fold into ␣-helical or random, extended chain structures, as well as soluble ␤-sheet structures that eventually precipitate as amyloid (Huang et al 2000; Teplow 1998; Zagorski 1999) . The relative ratios of the structures are strongly dependent on the solution conditions, with hydrophobic lipidlike environments encouraging ␣-helical structure and high ionic strength and midrange pH 4 -7 values favoring ␤-sheet. The ␣-helical and random, extended chain structures are monomeric, whereas the late-formed ␤-sheet structures in solution are aggregated (oligomeric) and neurotoxic (Lambert et al 1998; Sayre et al 1997) . Because the ␤-sheet structure is neurotoxic, a therapeutically useful inhibitor should bind or stabilize the ␣-helical, random, extended chain, or early formed ␤-sheet structures, which are very soluble and nontoxic.
Nicotine is a predominant component of cigarette smoke and is currently being used in pilot clinical studies for the treatment of AD (Emilien et al 2000; Wilson et al 1995) . The beneficial effects of this treatment have been attributed to an upregulation of nicotine receptors that are deficient in the AD brain, or possibly a protection from the A␤-induced neurotoxicity (Kihara et al 1997; Zamani et al 1997) . We and others have shown that nicotine may have a dual effect, in that besides promoting the upregulation of receptors or being neuroprotective, it may also inhibit ␤-amyloidosis. These conclusions were formulated on in vitro studies that established that nicotine slows down A␤(1-42) fibril formation (Moore et al 2000; Salomon et al 1996) and that this inhibition may be due to binding to the ␣-helical structure (Zagorski 1999) . The latter was based on nuclear magnetic resonance (NMR) studies of the homologous A␤(1-28) peptide that contains residues 1-28 of the A␤(1-42). Here we report an extension of this work with the A␤(1-42) and show that the inhibition does not result from binding to either the ␣-helical or random, extended chain structures.
Methods and Materials

Sample Preparation
Distilled/deionized water, nicotine, and cotinine were of the highest grade possible from commercial sources and were used without further purification. The organic solvents trifluoroacetic acid (TFA) and hexafluoroisopropanol (HFIP) were distilled under an inert atmosphere of nitrogen and stored in opaque bottles at 5°C. The perdeuterated sodium dodecyl sulfate (SDS-d 25 ), EDTA (Na 2 EDTA-d 12 ), 3-(trimethylsilyl)propionate-2,2,3,3-d 4 (TSP), and the solvent deuterium oxide (D 2 O) were obtained from Cambridge Isotopes (Andover, MA).
The synthetic A␤ peptides were obtained from commercial sources (Anaspec, San Jose, CA) or prepared using standard Fmoc chemistry on an automated (PerSeptive Biosystems [Foster City, CA] 9050-Plus) synthesizer. Uniformly (Ͼ95%) 15 Nlabeled A␤(1-42) were prepared biosynthetically from Escherichia coli as a recombinant fusion protein in minimal media containing 15 NH 4 Cl as the sole nitrogen source. The peptide was cleaved from the fusion protein at pH 8.3 using restriction protease Factor Xa. To isolate the cleaved A␤(1-42) from the fusion protein components, aggregation of the A␤(1-42) was induced by stirring in water (12 hours, pH 4 -7). The aggregated A␤(1-42) was collected by centrifugation (10,000 g, 20 min) and purified by reverse-phase high-performance liquid chromatography, with either a Zorbax-300 Bonded Silica (Rockland Technologies) or a Vydaq-259VHP822 column (Separation Group). The solvent system consisted of a linear gradient of Figure 1 . Overview of the formation of the ␤-amyloid (A␤) peptide from the amyloid precursor protein (APP), including the amino acid sequences for the A␤(1-40) and A␤(1-42) peptides. Depending upon conditions, the A␤ peptide exists in distinct conformations in solution, but in the amyloid deposit, only the oligomeric ␤-pleated sheet structure is present. Both peptides can aggregate into soluble ␤-sheet structures, which are neurotoxic and eventually precipitate as amyloid.
20 -80% acetonitrile in water that contained either 0.1-0.08% TFA or a sodium acetate buffer (5 mmol/L) at pH 8.0, which was heated to 55-60°C to improve peak resolution and purity (Boyes 1995) . Peptide identity, verified by mass spectrometry and NMR, had purity levels greater than 90%.
To disaggregate the A␤(1-42) and generate exclusively monomeric random, extended chain structure, the purified peptides were predissolved in neat TFA solution (Jao et al 1997; Zagorski et al 1999) . Trace amounts of TFA were removed by redissolving in HFIP (5:1 [mg:mL]) and then removing the HFIP with N 2 and vacuum (0.5 mm Hg, 2 hours). The disaggregation afforded by TFA allows the dry, unstructured, and monomeric A␤ to fold into its nativelike conformation in water, without potential interferences from trace organic cosolvents or small aggregates ("seeds") of the A␤.
The A␤(1-42) peptide solutions (0.60 mL) were prepared in 5-mm NMR tubes at concentrations of 0.1-1.4 mmol/L. The solvent-free, TFA-pretreated peptides were dissolved in either SDS-d 25 solution in H 2 O (for studies examining the effects of nicotine on the ␣-helical structure) or in 9:1 H 2 O:D 2 O (for studies examining the effects of nicotine on the random, extended chain structure). Stock solutions of (S)-(Ϫ)-cotinine, (R)-(ϩ)-nicotine, and (S)-(Ϫ)-nicotine were prepared in buffered water (pH 7.2) at 20 mmol/L concentrations, after which aliquots were added to the NMR solutions containing the A␤(1-42). All solutions contained 20 mmol/L sodium phosphate buffer at pH 7.2, 0.05 mmol/L Na 2 EDTA-d 12 , 0.05 mmol/L sodium azide (NaN 3 ), and 0.05 mmol/L TSP. The latter three components were included to remove trace metal ions, prevent microbial growth, and provide an internal chemical shift reference at 0 ppm, respectively. The SDS-d 25 concentration was kept high relative to the peptide concentration so that it was well above 8 mM (the Figure 2 . Upfield regions of the proton nuclear magnetic resonance ( 1 H NMR) spectra (600 MHz) for the ␤-amyloid (A␤) (1-42) (A) alone (0.5 mM) and with (B) 0.25 mM, (C) 0.50 mM, (D) 1.0 mM, and (E) 2.0 mM nicotine. The upper spectrum (F) corresponds to nicotine without the A␤(1-42). All solutions contained 80 mM sodium dodecyl sulfate (SDS-d 25 ) and 20 mM phosphate buffer at pH 7.2 and 25°C. The NMR peaks for nicotine are shown with the assignments. critical micelle concentration) and also above the average aggregation number (Henry and Sykes 1994) . To ensure that the buffer maintained pH 7.2 during the titrations, the pH of the solutions was checked with a special pH electrode (Microelectrodes) that fit inside the 5-mm NMR tube. The pH values were measured at room temperature and corrections for isotope effects or for the presence of SDS-d 25 were not performed, since control experiments showed that these substances did not significantly alter the pH.
Nuclear Magnetic Resonance Spectroscopy
All NMR spectra were acquired at 600 MHz using a Varian Inova-600 spectrometer. The NMR data were transferred to Indigo XS24 (Silicon Graphics) computer workstations and processed using the FELIX (version 97, Biosym) program.
Chemical shifts were referenced to an internal standard of TSP. The one-dimensional NMR spectra were acquired with a presaturation pulse that was applied during the recycle delay (2 sec) to suppress the H 2 O signal. Typically, most one-dimensional spectra had 8000-Hz spectral widths and 32-K complex data points. To further enhance the digital resolution and the signal to noise, before Fourier transformation the data were zero filled once and multiplied by a Lorentzian-to-Gaussian window function.
The two-dimensional 1 H-15 N heteronuclear single-quantum coherence (HSQC) experiments were recorded with a uniformly 15 N-labeled A␤(1-42) sample with 32 scans and 1024 complex points and the transmitter placed on the water signal (Bax and Grzesiek 1993) . The sweep widths were 6373.5 and 2000.0 Hz in the F 2 and F 1 dimensions, respectively. Phase-sensitive data were collected using time-proportional phase incrementation in the F 1 dimension, and pulsed field gradients were employed to minimize the artifact content of the spectra, suppress the intense H 2 O resonance, and select for the coherence transfer pathway, whereby magnetization passes from 15 N to 1 H for observation (Kay 1995) .
Results
The NMR approach has the distinct advantage of being able to sequence-specifically determine where a particular secondary structure is located within the primary sequence. Furthermore, for drug design the NMR method can provide valuable information about protein dynamics and specific data about the individual amino acid sidechains that bind to a particular ligand (Craik 1996; Hajduk et al 1999; Shuker et al 1996) . With sufficient distance and dihedral angle constraints, the NMR approach is also capable of rendering a complete three-dimensional structure.
Our sample preparation protocol ensures that the A␤(1-42) peptide adopts a well-defined, monomeric state before starting the NMR measurements. A major difficulty relates to the ease in which the A␤(1-42) aggregates and precipitates, which in turn creates problems in the reiteration of results. Because the peptide is very prone to time-dependent aggregation , all preaggregated peptide material was carefully removed from the samples before analysis (Jao et al 1997) . After this disaggregation was performed, the A␤ solutions were stable for several days at pH 7.2 and 5°C, with no precipitation or other spectral changes detected by NMR. Nuclear magnetic resonance diffusion and sedimentation equilibrium experiments confirmed that the A␤(1-42) adopts intact, nondegraded monomeric states (Shao et al, submitted) .
NMR Studies with the ␣-Helical Structure
Previous studies established that the A␤(1-28), A␤(1-40), and A␤(1-42) peptides fold into predominantly monomeric ␣-helical structures in lipid environments (Coles et al 1998; Marcinowski et al 1998; Shao et al 1999; Talafous et al 1994; Terzi et al 1997) . Because solution NMR studies with high-molecular-weight lipids (i.e., bilayers) are not feasible (due to slow tumbling rates), detergents such as the negatively charged SDS micelle are commonly used. Detergent micelles adequately mimic a membranelike environment and are frequently used in the structural studies of peptides and proteins (Henry and Sykes 1994) . Studies of the A␤ in lipidlike environments are important and may be pertinent to the native state, when bound to lipoproteins and albumin in human plasma (Biere et al 1996) . The present studies were undertaken to explore the effect of nicotine on the ␣-helical structure of the A␤(1-42) peptide in SDS solution.
Our previous NMR studies of the A␤(1-28) demon- strated that nicotine binds to the His side-chains when folded in an ␣-helical conformation (Salomon et al 1996; Zagorski 1999) . Figure 2 shows the upfield spectral regions in SDS solution of the A␤(1-42) alone (0.5 mmol/L) (Figure 2A Table 1 . The signals showing the most pronounced changes in chemical shifts are for the 2ЈH, 5ЈCH 2 , and N-CH 3 of nicotine, which are significantly less in magnitude than in previous NMR studies of the A␤(1-28) (Salomon et al 1996) . The binding is in fairly rapid . Presumed mechanism of ␤-amyloidosis for the ␤-amyloid (A␤) (1-42), which involves formation of a largely monomeric ␣-helical structure when bound to lipids and a predominantly monomeric random, extended chain structure in water solution. The ␣-helices are depicted with darkened cylinders, and the random coil or extended strand regions are drawn with wavy lines. The initially formed monomeric ␤-sheet structure is presumptive and is based on previous studies showing a reverse turn at Ser26 -Asn27-Lys28 -Gly29 (Hilbich et al 1991; Lee et al 1995) . In the brain, after proteolytic cleavage of the amyloid precursor protein (APP), the A␤(1-42) presumably monomeric structures that can aggregate into ␤-sheet-like structures as a result of possible brain microenvironmental changes such as localized regions of high peptide concentration or possibly small amounts of preformed ␤-sheet ("seed") material. The ␣-helical structure remains on the sodium dodecyl sulfate (SDS) or lipid surface and does not become imbedded into the hydrophobic interior. On the basis of the present nuclear magnetic resonance data, nicotine does not bind to the ␣-helical or random extended chain structures, suggesting that the inhibition may result from binding to a small ␤-sheet aggregate. A more effective nicotinelike amyloid inhibitor could be designed to bind to either the random, extended chain structure or ␣-helical structure, thereby slowing down aggregation to the toxic ␤-sheet structures that eventually produce amyloid.
that can facilitate the design of more specific drug candidates (Hajduk et al 1999; Shuker et al 1996) . When compared to conventional assays, the high-throughput HSQC-based screening approach can identify high-affinity ligands for protein targets with no known function.
The HSQC spectra were obtained in SDS solution at neutral pH with the A␤(1-42) at 0.25 mM concentration. Incremental titrations of (R)-(ϩ)-nicotine (the inactive isomer) and (S)-(Ϫ)-nicotine (the active isomer) were added to separate peptide solutions, in which the peptide concentration was constant (0.25 mM) and the nicotine concentration varied (0.050 mM, 0.15 mM, 0.25 mM, and 0.50 mM). The HSQC data were acquired within 10 min after each addition of the nicotine, and the pH was checked to ensure adequate buffering capacity. The NMR data showed no changes in chemical shifts, thus establishing that (R)-(ϩ)-nicotine and (S)-(Ϫ)-nicotine do not bind to the ␣-helical structure of the A␤(1-42) in a manner that induces changes in the backbone secondary structure.
NMR Studies with the Random, Extended Chain Structure
We have recently completely assigned the 1 H and 15 N NMR assignments of the A␤(1-42) in water solution at pH 7.2 (Shao et al, submitted) . Overall, the NMR data demonstrate that the peptide adopts a predominantly random, extended chainlike structure. These results suggest that by itself the A␤(1-42) peptide may be soluble and that brain microenvironmental changes in the AD brain may be required to induce a random, extended chain3␤-sheet conversion.
To analyze whether or not nicotine binds to the random, extended chainlike structure, we obtained two-dimensional HSQC data NMR with uniformly 15 N-labeled peptide, in an analogous manner as done in the SDS solution. The HSQC spectra were obtained at neutral pH with gradual titration of (R)-(ϩ)-nicotine (the inactive isomer) and (S)-(Ϫ)-nicotine (the active isomer) to separate A␤(1-42) solutions; the peptide concentration was maintained constant (0.20 mM), whereas the nicotine concentration varied (0.050 mM, 0.15 mM, 0.25 mM, and 0.50 mM). A representative HSQC is shown in Figure 3 for the A␤(1-42) alone and with 3 molar equivalents of (S)-(Ϫ)-cotinine, (R)-(ϩ)-nicotine, and (S)-(Ϫ)-nicotine. Cotinine is the major metabolite of nicotine and is readily excreted in the urine (Benowitz 1996) . The HSQC spectra show a narrow NH chemical shift dispersion, in support of a predominantly random, extended chain structure. The spectra for 0.40 mM of (S) 
Discussion
The molecular mechanisms for the accumulation of the A␤ peptide into insoluble amyloid remain largely unknown. A highly regarded mechanism involves an "amyloid-initiated cascade" pathway, where altered production, removal, and aggregation of the A␤ peptide initiate a sequence of events that leads to neuronal death (Selkoe 1999) . Besides amyloid, other lesions such as the neurofibrillary tangles are also abundant in AD brains, and it may happen that the tangles are more important in the pathogenesis of the disease. The tangles are intracellular deposits consisting of twisted filaments of the cytoskeletal Tau protein. However, since the majority of genetic and biological data support a critical role for amyloid formation in AD, the amyloid-initiated cascade hypothesis appears to be the most promising model for drug discovery.
An intense area of research in AD involves identifying potential inhibitors that either slow down or prevent the precipitation of the ␤-peptide into amyloid. Numerous studies indicate that A␤ amyloid inhibition is a good therapeutic approach for treatment of AD. Because monomeric and potentially toxic, proteolytic-resistant (GarzonRodriguez et al 1997; Roher et al 1996) , oligomeric species of A␤ exist in equilibrium within tissue culture medium (Esler et al 1996; Huang et al 1997; Johnstone et al 1996; Knauer et al 1992; LeVine 1995; Pike et al 1991) , the A␤ monomer is perhaps the best therapeutic target for binding by an amyloid-formation inhibitor. On the basis of reports of an inverse relationship between the risk of AD and cigarette smoking (Friedland 1994; Lerner et al 1997) , we have been studying the effects of nicotine and its metabolite, cotinine, on the solution conformations and aggregational properties of the ␤-peptide (Salomon et al 1996; Zagorski 1999) .
A possible mechanism for ␤-amyloidosis once the ␤-peptide is released from the APP is outlined in Figure 5 . The various pathways shown connect the in vitro biophysical studies to a natural situation that may exist in the brain. The model emphasizes a conformationally driven mechanism in which the three major solution structures of the ␤-peptide coexist in equilibrium: random coil (monomeric, water solution), ␣-helix (monomeric, in membranelike conditions similar to the SDS micelle), and the ␤-sheet (oligomeric). The aggregated ␤-sheet is the predominant structural motif in the amyloid plaques. When the aggregation reaches a critical mass, the ␤-sheet structure precipitates as amyloid, and reconversion back to soluble random coil or ␣-helical structures is no longer possible.
From the NMR data, we can conclude that nicotine does not show any significant binding to either the ␣-helical or the random extended chain structures. Thus, the nicotine inhibition to amyloid formation may result from binding to a small-sized soluble ␤-sheet aggregate, which is not yet detectable by NMR methods. Further studies with the A␤(1-42) ␤-sheet structure as well as with additional nicotine analogs are required to support this binding mode. Potential analogs could be synthesized with electrondonating substituents in the 4 position of the pyridine ring of nicotine, since this would increase the basicity of the N-1 nitrogen and perhaps increase binding. An analogous structural motif may be involved in the binding of the A␤ peptide to transthyretin, a normal protein component of plasma (Schwarzman et al 1994) . More recent work established that the A␤(1-42) binds to the ␣7 nicotinic acetylcholine receptor site, and the critical epitope is located with the Val12-Lys28 region (Wang et al 2000) . Although it is not yet known whether nicotine does indeed bind to the A␤ in the human brain, the possibility of such an event is intriguing. We anticipate that additional studies (directed at monomeric A␤) may facilitate the development of more selective nicotinelike inhibitors to prevent amyloid plaque formation in AD.
